Neovascular age-related macular degeneration: roundtable.
Several recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related maculopathy (age-related macular degeneration [ARMD]). Concurrent with progress in isolating clinically relevant subtypes of neovascular ARMD, several therapies have been introduced that show promise for halting progression of this disorder. However, data from controlled clinical trials to test the relative efficacy of different management strategies across these subtypes of disease presentation remain limited. In addition, strategies to control ARMD may evolve quickly as more is learned about how specific molecular events, such as cell-mediated inflammation and angiogenesis, contribute to disease expression. A roundtable of investigators was convened to discuss and summarize recent progress in the treatment of ARMD. Case studies were then presented to provide an opportunity for experts to reveal their specific thought processes in the approach to neovascular ARMD based on their own interpretation of current clinical data and empirical experience.
Singerman
Lawrence J
LJ
Retina Associates of Cleveland, Cleveland, OH, USA.
Brucker
Alexander J
AJ
Jampol
Lee M
LM
Lim
Jennifer I
JI
Rosenfeld
Philip
P
Schachat
Andrew P
AP
Spaide
Richard F
RF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged